Mi a cardiovascularis kockázat csökkentésének leghatékonyabb módja 2-es típusú diabetes mellitusban?

Translated title of the contribution: The most effective approach in reduction of cardiovascular risk in type 2 diabetes mellitus?

Kornél Simon, Edit Dobó, Tamás Nádasy, Ibolya Retin, I. Rácz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It is well known that the target blood glucose values are not fulfilled in treatment of patients with type 2 diabetes mellitus. (UKPDS) The high mortality rate in type 2 diabetes mellitus is associated with the augmented cardiovascular risk. It is well documented, that the beneficial influence of high blood pressure, dyslipidaemia, and hypercoagulation compared to hyperglycaemia, is a more powerful approach in reduction of cardiovascular risk in type 2 diabetes mellitus. The effect of medical interventions on alteration of cardiovascular risk and glucose homeostasis is not always concordant: betablockers mandatorily reduce cardiovascular risk, but may result in deterioration of blood glucose values, sulfanylurea drugs effectively reduce hyperglycaemia, but could paradoxically increase the cardiovascular risk. The acarbose, methformin, thiazolidindione, fibric acid treatment improves the profile of vascular risk factors, additionally could have a beneficial metabolic effect resulting in reducing cardiovascular risk in patients with type 2 diabetes mellitus. In conclusion: the cardiovascular risk in type 2 diabetes mellitus can be most effectively influenced by reduction of high blood pressure, dyslipidaemia, and dysfunction of haemostasis. The improvement of glucose homeostasis is, novel medical interventions seem to be important tools in reducing cardiovascular risk in patients with type 2 diabetes mellitus.

Original languageHungarian
Pages (from-to)1443-1446
Number of pages4
JournalOrvosi Hetilap
Volume147
Issue number31
Publication statusPublished - Aug 6 2006

Fingerprint

Risk Reduction Behavior
Type 2 Diabetes Mellitus
Dyslipidemias
Hyperglycemia
Blood Glucose
Homeostasis
Acarbose
Hypertension
Glucose
Hemostasis
Mortality
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mi a cardiovascularis kockázat csökkentésének leghatékonyabb módja 2-es típusú diabetes mellitusban? / Simon, Kornél; Dobó, Edit; Nádasy, Tamás; Retin, Ibolya; Rácz, I.

In: Orvosi Hetilap, Vol. 147, No. 31, 06.08.2006, p. 1443-1446.

Research output: Contribution to journalArticle

Simon, Kornél ; Dobó, Edit ; Nádasy, Tamás ; Retin, Ibolya ; Rácz, I. / Mi a cardiovascularis kockázat csökkentésének leghatékonyabb módja 2-es típusú diabetes mellitusban?. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 31. pp. 1443-1446.
@article{95a12136cd224fbfb73dd3102b280f84,
title = "Mi a cardiovascularis kock{\'a}zat cs{\"o}kkent{\'e}s{\'e}nek leghat{\'e}konyabb m{\'o}dja 2-es t{\'i}pus{\'u} diabetes mellitusban?",
abstract = "It is well known that the target blood glucose values are not fulfilled in treatment of patients with type 2 diabetes mellitus. (UKPDS) The high mortality rate in type 2 diabetes mellitus is associated with the augmented cardiovascular risk. It is well documented, that the beneficial influence of high blood pressure, dyslipidaemia, and hypercoagulation compared to hyperglycaemia, is a more powerful approach in reduction of cardiovascular risk in type 2 diabetes mellitus. The effect of medical interventions on alteration of cardiovascular risk and glucose homeostasis is not always concordant: betablockers mandatorily reduce cardiovascular risk, but may result in deterioration of blood glucose values, sulfanylurea drugs effectively reduce hyperglycaemia, but could paradoxically increase the cardiovascular risk. The acarbose, methformin, thiazolidindione, fibric acid treatment improves the profile of vascular risk factors, additionally could have a beneficial metabolic effect resulting in reducing cardiovascular risk in patients with type 2 diabetes mellitus. In conclusion: the cardiovascular risk in type 2 diabetes mellitus can be most effectively influenced by reduction of high blood pressure, dyslipidaemia, and dysfunction of haemostasis. The improvement of glucose homeostasis is, novel medical interventions seem to be important tools in reducing cardiovascular risk in patients with type 2 diabetes mellitus.",
keywords = "Cardiovascular risk, Glucose paradoxon, Metabolic syndrome, Type 2 diabetes mellitus",
author = "Korn{\'e}l Simon and Edit Dob{\'o} and Tam{\'a}s N{\'a}dasy and Ibolya Retin and I. R{\'a}cz",
year = "2006",
month = "8",
day = "6",
language = "Hungarian",
volume = "147",
pages = "1443--1446",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "31",

}

TY - JOUR

T1 - Mi a cardiovascularis kockázat csökkentésének leghatékonyabb módja 2-es típusú diabetes mellitusban?

AU - Simon, Kornél

AU - Dobó, Edit

AU - Nádasy, Tamás

AU - Retin, Ibolya

AU - Rácz, I.

PY - 2006/8/6

Y1 - 2006/8/6

N2 - It is well known that the target blood glucose values are not fulfilled in treatment of patients with type 2 diabetes mellitus. (UKPDS) The high mortality rate in type 2 diabetes mellitus is associated with the augmented cardiovascular risk. It is well documented, that the beneficial influence of high blood pressure, dyslipidaemia, and hypercoagulation compared to hyperglycaemia, is a more powerful approach in reduction of cardiovascular risk in type 2 diabetes mellitus. The effect of medical interventions on alteration of cardiovascular risk and glucose homeostasis is not always concordant: betablockers mandatorily reduce cardiovascular risk, but may result in deterioration of blood glucose values, sulfanylurea drugs effectively reduce hyperglycaemia, but could paradoxically increase the cardiovascular risk. The acarbose, methformin, thiazolidindione, fibric acid treatment improves the profile of vascular risk factors, additionally could have a beneficial metabolic effect resulting in reducing cardiovascular risk in patients with type 2 diabetes mellitus. In conclusion: the cardiovascular risk in type 2 diabetes mellitus can be most effectively influenced by reduction of high blood pressure, dyslipidaemia, and dysfunction of haemostasis. The improvement of glucose homeostasis is, novel medical interventions seem to be important tools in reducing cardiovascular risk in patients with type 2 diabetes mellitus.

AB - It is well known that the target blood glucose values are not fulfilled in treatment of patients with type 2 diabetes mellitus. (UKPDS) The high mortality rate in type 2 diabetes mellitus is associated with the augmented cardiovascular risk. It is well documented, that the beneficial influence of high blood pressure, dyslipidaemia, and hypercoagulation compared to hyperglycaemia, is a more powerful approach in reduction of cardiovascular risk in type 2 diabetes mellitus. The effect of medical interventions on alteration of cardiovascular risk and glucose homeostasis is not always concordant: betablockers mandatorily reduce cardiovascular risk, but may result in deterioration of blood glucose values, sulfanylurea drugs effectively reduce hyperglycaemia, but could paradoxically increase the cardiovascular risk. The acarbose, methformin, thiazolidindione, fibric acid treatment improves the profile of vascular risk factors, additionally could have a beneficial metabolic effect resulting in reducing cardiovascular risk in patients with type 2 diabetes mellitus. In conclusion: the cardiovascular risk in type 2 diabetes mellitus can be most effectively influenced by reduction of high blood pressure, dyslipidaemia, and dysfunction of haemostasis. The improvement of glucose homeostasis is, novel medical interventions seem to be important tools in reducing cardiovascular risk in patients with type 2 diabetes mellitus.

KW - Cardiovascular risk

KW - Glucose paradoxon

KW - Metabolic syndrome

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=33750124225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750124225&partnerID=8YFLogxK

M3 - Article

C2 - 16981416

AN - SCOPUS:33750124225

VL - 147

SP - 1443

EP - 1446

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 31

ER -